ArticleActa dermato-venereologica2021
Impact of Itch on Sleep Disturbance in Patients with Prurigo Nodularis.
Article in Acta dermato-venereologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of Chronic Nodular Prurigo on Quality of Life: A Systematic Review of the Literature.Dermatology and therapy · 2026Pooled it
- Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.JAMA dermatology · 2025Trial
- Cumulative Life Course Impairment in Atopic Dermatitis: A Comprehensive Review.Medical sciences (Basel, Switzerland) · 2026Review
- The State of the Art in Chronic Prurigo Nodularis.Dermatology and therapy · 2026Review
- A Conceptual Disease Model of Symptoms and Impacts in Adults with Prurigo Nodularis: A Qualitative and Literature-Informed Study.Dermatology and therapy · 2026Article
- Quantitative Evaluation of Nemolizumab Pharmacokinetics and Efficacy in Prurigo Nodularis: A Population Pharmacokinetics and Model-Based Meta-analysis Approach.Dermatology and therapy · 2025Article
- Content Validity and Psychometric Validation of an Adapted Version of the Subject Sleep Diary in Prurigo Nodularis.Dermatology and therapy · 2025Article
- Risk of incident sleep disorders in patients with prurigo nodularis: A population-level analysis using The Health Improvement Network.JAAD international · 2023Article
- [Chronic prurigo].Dermatologie (Heidelberg, Germany) · 2023Review
- The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis.Dermatology and therapy · 2023Article
- Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.EClinicalMedicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.